Core Insights - ZyVersa Therapeutics is focused on developing first-in-class drugs for renal and inflammatory diseases, particularly targeting diabetic kidney disease (DKD) through addressing lipotoxicity [1][2][8] - The company is advancing its Cholesterol Efflux Mediator™ VAR 200, which aims to alleviate kidney injury by mediating the removal of excess lipids from kidney cells [6][8] Summary of Key Findings - Diabetic conditions lead to significant lipid metabolic abnormalities in kidney cells, resulting in lipid accumulation that triggers inflammation and fibrosis, contributing to DKD progression [3][4][6] - Impaired cholesterol efflux is identified as a critical factor in DKD pathology, exacerbating lipid accumulation and leading to structural damage in kidney filtration systems [3][7] - The activation of inflammasomes in kidney cells due to lipid overload initiates an inflammatory response, creating a vicious cycle that further declines renal function [4][6] Market Context - Over 130,000 patients in the US progress to renal failure annually, with more than 800,000 living with renal failure requiring dialysis or transplant [2] - The global drug market for kidney diseases was valued at $18 billion in 2024, with projections of $30 billion by 2034 [6]